{"id":"NCT03449147","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN030)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-15","primaryCompletion":"2020-08-20","completion":"2020-10-30","firstPosted":"2018-02-28","resultsPosted":"2021-09-02","lastUpdate":"2021-09-02"},"enrollment":1317,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Cough"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Gefapixant 15 mg BID","otherNames":["MK-7264"]},{"type":"DRUG","name":"Gefapixant 45 mg BID","otherNames":["MK-7264"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Gefapixant 15 mg BID","type":"EXPERIMENTAL"},{"label":"Gefapixant 45 mg BID","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this study are to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period, and to determine the safety and tolerability of gefapixant. The primary hypothesis is that at least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24 hours) at Week 24.","primaryOutcome":{"measure":"Model-Based Geometric Mean Ratio (GMR) of 24-Hour Coughs Per Hour at Week 24/Baseline","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Placebo","deltaMin":0.43,"sd":null},{"arm":"Gefapixant 15 mg BID","deltaMin":0.43,"sd":null},{"arm":"Gefapixant 45 mg BID","deltaMin":0.37,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.875"},{"comp":"OG000 vs OG002","p":"0.031"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":171,"countries":["United States","Australia","Canada","China","Colombia","Czechia","Denmark","Germany","Guatemala","Hungary","Israel","Italy","Malaysia","New Zealand","Peru","Poland","South Africa","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["35569802","35248186"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":432},"commonTop":["Dysgeusia","Nasopharyngitis","Headache","Nausea","Upper respiratory tract infection"]}}